July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
A systematic review of the effectiveness of pharmacological agents for the treatment of uveitic macular oedema (UMO)
Author Affiliations & Notes
  • Mohammad O S Tallouzi
    Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
    Academic Unit of Ophthalmology, Birmingham and Midland Eye Centre, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom
  • Robert John Barry
    Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
  • David J Moore
    Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
  • Melanie J Calvert
    Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
  • Philip Ian Murray
    Academic Unit of Ophthalmology, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, North Chicago, Illinois, United States
  • Jonathan M Mathers
    Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
  • Alastair K Denniston
    Department of Ophthalmology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust , Birmingham, United Kingdom
  • Footnotes
    Commercial Relationships   Mohammad Tallouzi, None; Robert Barry, None; David Moore, None; Melanie Calvert, None; Philip Murray, None; Jonathan Mathers, None; Alastair Denniston, None
  • Footnotes
    Support  NIHR
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 403. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mohammad O S Tallouzi, Robert John Barry, David J Moore, Melanie J Calvert, Philip Ian Murray, Jonathan M Mathers, Alastair K Denniston; A systematic review of the effectiveness of pharmacological agents for the treatment of uveitic macular oedema (UMO). Invest. Ophthalmol. Vis. Sci. 2018;59(9):403.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Macular oedema is the leading cause of sight-loss in patients with uveitis. There is no consensus over the optimal treatment of UMO. Our aim was to review systematically the effectiveness of pharmacological agents used to treat UMO.

Methods : The protocol was registered on PROSPERO (CRD42015019170). Standard methodology was employed to identify, select, extract data and assess the quality of the included studies. Bibliographic databases (Cochrane Library, MEDLINE, EMBASE and CINAHL) and clinical trials registers were searched on 10 February 2017. There were no restrictions on language of publications. The review was reported in accordance with PRISMA guidelines.

Results : 31 studies were included (25 RCTs and 6 cohort studies). In 14 studies, UMO was the target condition. In 11 studies, UMO was present in a subset of patients only; such studies frequently failed to report results from the UMO subgroup, restricting their contribution to the review.

Pharmacological agents were grouped into 6 classes with studies comparing agents to placebo, an agent within the same class or a different class.Table 1 reports the class comparison of all included studies.

20 studies assessed corticosteroids by oral (n=3), intravitreal (n=12) or other (n=5) route of administration. All forms of corticosteroid were effective ieffective (improved visual acuity and reduced macular thickness).

9 studies evaluated the use of non-corticosteroid immunomodulatory class agents, including T cell inhibitor (n=1), antimetabolites (n=2), and biological agents (n=6).

Other treatments classes evaluated carbonic anhydrase inhibitors (n=3), NSAIDs (n=3), anti-VEGF agents (n=4) and vitamin E (n=1).

Corticosteroid and immunomodulatory drugs were effective treatment for UMO; anti-VEGF had variable results; carbonic anhydrase inhibitors, NSAIDs and vitamin E were not effective.

A meta-analysis could not be undertaken due to variation in drug dosage, route of administration and study design.

Conclusions : This systematic review is the largest in the field to date that presents the available evidence to support pharmacological agents in UMO; however, it was not possible to conduct a meta-analysis on any single agent. This review also highlights areas where the evidence base is still lacking, and appropriately focused trials are needed to inform best treatment to tackle this sight-threatening condition in uveitis patients.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×